Biodexa enters into agreements to acquire exclusive worldwide license to tolimidone, a phase ii ready asset for type 1 diabetes

Cardiff , nov. 27, 2023 (globe newswire) -- 27 november 2023 biodexa pharmaceuticals plc (“biodexa” or the “company”) biodexa enters into agreements to acquire exclusive worldwide license to tolimidone, a phase ii ready asset for type 1 diabetes highlights: acquisition of exclusive worldwide license to develop and commercialize tolimidone phase ii ready with encouraging signals of Β cell proliferation in preclinical models extensive safety database as tolimidone exposed to approximately [700] patients in other indications biodexa pharmaceuticals plc, (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that it has entered into an agreement for the assignment of  adhera therapeutics, inc.'s  (“adhera's”) rights to tolimidone (formerly coded mlr-1023) under an exclusive, worldwide, sub-licensable license from melior pharmaceuticals i, inc. (“melior”) to develop, manufacture, commercialize or otherwise exploit tolimidone.      about tolimidone tolimidone was originally discovered by pfizer inc. (“pfizer”) and was developed through phase ii for the treatment of gastric ulcers.
BDRX Ratings Summary
BDRX Quant Ranking